Antibody-based immunotherapy for ovarian cancer: where are we at?

Cytoreductive surgery and chemotherapy continue to be the mainstay of ovarian cancer treatment. However, as mortality from advanced ovarian cancer remains very high, novel therapies are required to be integrated into existing treatment regimens. Immunotherapy represents an alternative and rational t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2014-02, Vol.25 (2), p.322-331
Hauptverfasser:	Tse, B.W.C., Collins, A., Oehler, M.K., Zippelius, A., Heinzelmann-Schwarz, V.A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Bispecific - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antibodies, Monoclonal, Murine-Derived antibody Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences clinical trials Clinical Trials as Topic Daclizumab diagnosis Diphtheria Toxin - therapeutic use Female Female genital diseases gynaecological cancers Gynecology. Andrology. Obstetrics Humans Immunoglobulin G - therapeutic use immunology Immunotherapy Interleukin-2 - therapeutic use Ipilimumab Medical sciences Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Ovarian Neoplasms - drug therapy Pharmacology. Drug treatments Recombinant Fusion Proteins - therapeutic use treatment regimens Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!